title: A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy.
abstract: Significant advances in the understanding of the pathophysiology of pulmonary arterial hypertension over the past two decades have led to the development of targeted therapies and improved patient outcomes. Currently, a broad armamentarium of pulmonary arterial hypertension-specific drugs exists to assist in the treatment of this complex disease state. In this manuscript, we provide a comprehensive review of the current Food and Drug Administration (FDA)-approved pulmonary arterial hypertension-specific therapies, and their supporting evidence for adults, targeting the nitric oxide, soluble guanylate cyclase, endothelin, and prostacyclin pathways.
authors.affiliation: Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, 1600 SW Archer Rd, M452, P.O. Box 100225, Gainesville, FL 32610, USA. aliataya@gmail.com.
authors.forename: Ali
authors.initials: A
authors.lastname: Ataya
authors.affiliation: Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, 1600 SW Archer Rd, M452, P.O. Box 100225, Gainesville, FL 32610, USA. copej@shands.ufl.edu.
authors.forename: Jessica
authors.initials: J
authors.lastname: Cope
authors.affiliation: Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, 1600 SW Archer Rd, M452, P.O. Box 100225, Gainesville, FL 32610, USA. hassan.alnuaimat@medicine.ufl.edu.
authors.forename: Hassan
authors.initials: H
authors.lastname: Alnuaimat
keywords: endothelin; nitric oxide; prostacyclin; pulmonary arterial hypertension; pulmonary hypertension; soluble guanylate cyclase